Antibody Discovery: Why Early Design Matters

Antibody Discovery: Why Early Design Matters

The development of any antibody format begins with identifying sequences capable of binding a target with the desired specificity and affinity. AI- and machine learning-driven methods are increasingly complimenting experimental workflows. These tools can support sequence design, predict binding interactions, and guide optimization strategies. While still evolving, these tools are increasingly integrated into early discovery phases to improve efficiency and reduce experimental burden.

Ultimately, antibody performance is determined at the sequence level. Early design decisions influence not only binding properties, but also expression yield, stability, and manufacturability. Key considerations include:

• Framework selection and compatibility
• Domain orientation and structural stability
• Aggregation propensity and solubility
• Immunogenicity risk

Because these factors are interconnected, even small sequence variations can have significant downstream consequences. This is especially important, particularly when moving beyond standard IgG formats, where structural constraints are less forgiving.

Optimizing Expression and Production

Once candidate antibody sequences are identified, they must be expressed efficiently and reproducibly. For full-length IgG antibodies, mammalian expression systems such as Chinese hamster ovary (CHO) or HEK cells are typically used to ensure proper folding and glycosylation. In contrast, smaller formats such as scFvs and nanobodies can often be expressed in bacterial or yeast systems, offering faster and more cost-effective production.

Several factors influence expression outcomes:

• Codon optimization, which aligns gene sequences with host-specific translation preferences
• Signal peptide selection, which affects secretion efficiency
• Heavy-to-light chain ratios, which impact correct assembly in IgG-like formats
• Expression system choice, which determines post-translational modifications

Optimization at this stage is essential for achieving sufficient yield and consistency.

Antibody Discovery Process: Choose the Right Format for the Right Problem

Recombinant antibody formats offer a highly adaptable platform for therapeutic development. Each format provides distinct advantages but also introduces specific technical challenges. Successful antibody development depends on aligning biological function, molecular architecture, expression strategy and developability considerations. Selecting the right format early, and designing it thoughtfully, can significantly influence the likelihood of downstream success.

Learn more about antibody expression and production by downloading our new A Guide to Antibodies eBook.

About the authors: Prassanna Rao and Fränze Vorreiter are Synthesis Experts at GENEWIZ. They and their team translate complex biological challenges into precise, actionable solutions for researchers worldwide. Their expertise spans designing complex cloning strategies for de novo synthesis, synthetic libraries, recombinant antibody production, and viral production services.